WO2026103873 - HETEROCYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF
National phase entry is expected:
Publication Number
WO/2026/103873
Publication Date
21.05.2026
International Application No.
PCT/CN2025/135098
International Filing Date
14.11.2025
Title **
[English]
HETEROCYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF
[French]
COMPOSÉ HÉTÉROCYCLIQUE ET UTILISATION PHARMACEUTIQUE DE CELUI-CI
[Chinese]
一种杂环化合物及其在医药上的应用
Applicants **
HANGZHOU BAICREAT PHARMA-TECH CO., LTD.
Inventors
ZHANG, Fengmin
GU, Dongyan
ZHANG, Sicheng
Priority Data
202411632466.3
15.11.2024
CN
202510010069.0
03.01.2025
CN
202510451883.6
11.04.2025
CN
202510584094.X
07.05.2025
CN
202511027367.7
24.07.2025
CN
202511228002.0
29.08.2025
CN
202511428526.4
01.10.2025
CN
202510004566.X
02.01.2025
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3190 | |
| EPO | Filing, Examination, Granting | 20943 | |
| Japan | Filing, Examination, Granting | 2578 | |
| South Korea | Filing, Examination, Granting | 3090 | |
| USA | Filing, Examination, Granting | 6590 |
Total:
36,391
Abstract[English]
The present invention relates to the technical field of medicine, and specifically relates to a VAV1 degrader, a preparation method therefor, and the pharmaceutical use thereof. Provided in the present invention are a VAV1 degrader of formula (I), and a composition thereof and the use thereof. The compound can be used for treating or preventing VAV1-mediated diseases or conditions and related diseases or conditions.[French]
La présente invention concerne le domaine technique de la médecine, et concerne plus particulièrement un dégradeur de VAV1, un procédé de préparation de celui-ci, et l'utilisation pharmaceutique de celui-ci. La présente invention fournit un dégradeur de VAV1 de formule (I), ainsi qu'une composition de celui-ci et l'utilisation de celui-ci. Le composé peut être utilisé pour traiter ou prévenir des maladies ou affections médiées par VAV1 et des maladies ou affections associées.[Chinese]
本发明涉及医药技术领域，具体涉及VAV1降解剂、其制备方法及其在医药上的应用。本发明提供了一种式(I)所述VAV1降解剂及其组合物和用途，所述化合物可以用于治疗或预防VAV1介导的疾病或病症及相关疾病或病症。